Keros Therapeutics, Inc.

KROS

Keros Therapeutics, Inc.

KROS

Insider Sentiment (TTM):

Last Purchase:2026-06-15Last Sale:2026-06-11Shares Purchased (TTM):5,000Shares Sold (TTM):10,205,392

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:18,167,964Shares Outstanding:19,629,906Institutional Ownership Pct.:92.55%

Earnings Market Reaction:

Filing Date:2026-08-03Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	258	281	287	693	690	721	560	531	406	442	331	288
Accounts Receivable Net Current	0	0	4	3	16	17	3	0	0	0	0	-
Prepaid Expense And Other Assets Current	7	7	22	22	27	22	26	21	27	20	16	17
Income Taxes Receivable	2	2	2	-	-	-	0	-	-	-	-	-
Assets Current	267	291	315	719	733	760	589	552	433	463	347	304
Operating Lease Right Of Use Asset	16	16	17	17	18	19	19	20	15	15	15	16
Property Plant And Equipment Net	4	4	4	5	5	4	4	4	4	4	4	3
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	-	-	0	0	0	0	2	2	2	2	2	2
Assets	288	312	338	743	757	785	616	579	455	486	370	326
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	1	2	2	5	7	5	5	7	5	5	4
Operating Lease Liability Current	3	3	2	2	2	2	2	2	1	1	1	1
Accrued Liabilities Current	8	9	16	15	20	17	21	22	14	13	18	12
Contract With Customer Liability Current	-	-	-	0	1	3	-	-	-	-	-	-
Accrued Income Taxes Current	-	-	-	4	6	10	-	-	-	-	-	-
Liabilities Current	12	13	20	24	35	39	27	29	21	19	24	17
Operating Lease Liability Noncurrent	13	14	14	15	16	16	17	17	13	13	13	14
Liabilities	25	27	35	39	50	56	44	46	34	32	38	30
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Value	-385	-385	-385	-	-	-	0	-	-	-	-	-
Additional Paid In Capital	1,181	1,176	1,169	1,162	1,158	1,149	1,140	1,056	891	878	714	637
Retained Earnings Accumulated Deficit	-534	-505	-482	-458	-451	-420	-569	-523	-470	-425	-381	-341
Stockholders Equity	262	286	303	704	707	729	572	533	421	454	332	296
Liabilities And Stockholders Equity	288	312	338	743	757	785	616	579	455	486	370	326
Series A Preferred Stock	-	0	0	0	0	-	0	-	-	-	-	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	-
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Shares Issued	41	41	41	41	41	41	41	39	36	36	32	30
Shares Outstanding	20	20	20	41	41	41	41	39	36	36	32	30
Treasury Stock Common Shares	21	21	21	-	-	-	0	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.28%	2.46%	-8.37%	-	-	-	-	-	-	-	-	-
2025	2.83%	-1.96%	5.09%	5.55%	11.38%	4.37%	11.69%	34.38%	22.68%	-22.95%	-16.41%	-18.74%
2024	-19.52%	-21.53%	-10.16%	-0.11%	24.34%	33.83%	-13.11%	-75.29%	-82.18%	2.56%	28.61%	28.61%
2023	-	-	-	-10.34%	-21.13%	-31.57%	-3.31%	25.47%	80.69%	-3.23%	-14.38%	-23.20%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	21.96	22.62	15.45	29.86	21.11	19.29	21.45	19.03	20.37	24.74	14.25	18.23
Quick Ratio	21.38	22.11	14.36	28.93	20.34	18.74	20.50	18.31	19.10	23.65	13.59	17.24
Working Capital	254.73M	277.82M	295.02M	695.22M	698.10M	720.13M	561.44M	523.04M	411.47M	444.41M	322.92M	287.73M
Leverage & Debt
Debt to Equity	0.10	0.09	0.12	0.06	0.07	0.08	0.08	0.09	0.08	0.07	0.11	0.10
Debt Ratio	0.09	0.09	0.10	0.05	0.07	0.07	0.07	0.08	0.07	0.07	0.10	0.09
Efficiency & Turnover
Asset Turnover TTM	0.03	0.06	0.51	0.37	0.38	0.34	0.01	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	-	97.30	4.72	2.87	12.40	14.89	148.31	217.54	5.39	352.52	345.66	-
Receivables Turnover TTM	-	3.75	77.37	127.17	29.44	24.51	2.46	1.68	67.75	1.04	1.06	-
Per Share Metrics
Diluted EPS TTM	-4.20	-4.34	2.30	1.59	0.46	0.10	-5.00	-4.83	-4.65	-4.49	-5.20	-4.80
Free Cash Flow Per Share TTM	5.84	-2.97	2.85	-1.81	-2.65	1.07	-4.35	-3.79	-4.05	-3.84	-4.31	-4.14
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-675.82%	-332.55%	27.69%	17.67%	0.13%	-4.80%	-5,938.96%	-31,341.63%	-69,615.13%	-76,732.91%	-112,543.71%	-1,943,075.00%
Net Profit Margin TTM	-553.88%	-256.60%	35.65%	26.12%	8.06%	1.96%	-5,277.55%	-27,890.94%	-62,012.55%	-68,505.13%	-101,319.21%	-1,780,837.50%
Growth Metrics
Net Revenue Growth (1Y)	-93.55%	-84.55%	6,774.96%	37,798.31%	85,820.30%	91,657.69%	2,250.99%	8,037.50%	-	-	-	-99.96%
Net Income Growth (1Y)	-542.97%	-2,121.49%	-146.44%	-135.50%	-111.17%	-102.63%	22.46%	27.45%	32.81%	37.84%	46.15%	73.95%
EPS Growth (1Y)	-1,008.59%	-4,276.80%	-146.71%	-132.85%	-109.93%	-102.31%	-3.68%	0.59%	8.90%	9.58%	25.28%	49.80%
Valuation Metrics
P/E TTM	-2.55	-2.55	8.71	9.97	28.88	98.12	-3.16	-12.02	-9.82	-14.74	-7.65	-6.64
P/B TTM	0.81	0.76	2.50	0.91	0.77	0.57	1.04	4.10	3.92	5.20	3.52	3.20
P/S TTM	14.11	6.53	3.11	2.60	2.33	1.92	166.94	3,353.14	6,088.25	10,095.62	7,753.76	118,227.96
Market Cap	211.86M	216.71M	757.82M	642.66M	542.18M	413.30M	592.64M	2.18B	1.65B	2.36B	1.17B	945.82M
Enterprise Value	-45.74M	-66.23M	468.96M	-52.26M	-149.48M	-308.69M	31.26M	1.65B	1.24B	1.92B	838.46M	656.72M
Calculated Values
Free Cash Flow TTM	115.72M	-58.25M	105.95M	-73.52M	-107.53M	43.31M	-162.80M	-142.50M	-146.15M	-137.18M	-126.97M	-122.77M
Net Debt	-257.61M	-282.95M	-288.86M	-694.92M	-691.66M	-721.99M	-561.38M	-532.13M	-407.08M	-443.66M	-332.36M	-289.11M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-15Purchase

Owner: Bienaime, Jean Jacques

Title: -

Shares: 1,000

Price/Share: $10.19

Value: $10,190.00

Shares Owned: 17,592

Relationship: Director

Ownership: Direct

2026-06-11Sale

Owner: Newton, Charles W.

Title: -

Shares: 550

Price/Share: $10.04

Value: $5,522.00

Shares Owned: 12,665

Relationship: Director

Ownership: Direct

2026-06-04Sale

Owner: Farzan, Nima

Title: -

Shares: 2,625

Price/Share: $10.73

Value: $28,166.25

Shares Owned: 9,767

Relationship: Director

Ownership: Direct

2026-06-04Sale

Owner: Seth, Alpna

Title: -

Shares: 2,625

Price/Share: $10.72

Value: $28,140.00

Shares Owned: 9,767

Relationship: Director

Ownership: Direct

2026-06-04Sale

Owner: Knowles, Julius

Title: -

Shares: 2,625

Price/Share: $10.73

Value: $28,166.25

Shares Owned: 10,958

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-15	Bienaime, Jean Jacques	Director	-	Direct	Purchase	1,000	10.19	$10,190.00	17,592	4
2026-06-11	Newton, Charles W.	Director	-	Direct	Sale	550	10.04	$5,522.00	12,665	4
2026-06-04	Farzan, Nima	Director	-	Direct	Sale	2,625	10.73	$28,166.25	9,767	4
2026-06-04	Seth, Alpna	Director	-	Direct	Sale	2,625	10.72	$28,140.00	9,767	4
2026-06-04	Knowles, Julius	Director	-	Direct	Sale	2,625	10.73	$28,166.25	10,958	4
2026-05-15	Bienaime, Jean Jacques	Director	-	Direct	Purchase	1,000	10.58	$10,580.00	9,450	4
2026-04-15	Bienaime, Jean Jacques	Director	-	Direct	Purchase	1,000	11.70	$11,700.00	8,450	4
2026-03-09	Bienaime, Jean Jacques	Director	-	Direct	Purchase	2,000	11.21	$22,420.00	7,450	4
2026-02-19	Seehra, Jasbir	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,015	16.17	$113,432.55	385,708	4
2026-02-18	Regnante, Keith	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	4,739	16.35	$77,482.65	39,261	4
2026-02-18	Lerner, Lorena Raquel	Officer	Chief Science Officer	Direct	Sale	3,873	16.35	$63,323.55	31,127	4
2026-02-18	Cho, Esther	Officer	SVP, General Counsel	Direct	Sale	4,745	16.35	$77,580.75	39,755	4
2025-10-15	Schneeberger, Daniel, Ada…	TenPercentOwner	-	Indirect	Sale	5,389,264	17.75	$95,659,436.00	0	4
2025-10-15	Pontifax, (China) Iv L.P.…	TenPercentOwner	-	Indirect	Sale	4,787,331	17.75	$84,975,125.25	0	4
2025-04-09	Adar1, Partners, Lp, Adar…	TenPercentOwner	-	Indirect	Purchase	934,258	9.86	$9,211,783.88	4,392,737	4
2024-08-13	Gordon, Carl L	Director	-	Indirect	Sale	250,000	44.01	$11,002,500.00	119,522	4
2024-08-13	Orbimed, Genesis Gp Llc, …	Director	-	Indirect	Sale	250,000	44.01	$11,002,500.00	119,522	4
2024-01-04	Regnante, Keith	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	40,000	45.29	$1,811,600.00	0	4/A
2023-11-04	Regnante, Keith	Officer	Chief Financial Officer	Direct	Sale	40,000	45.29	$1,811,600.00	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.55%

Inst. Shares: 18,167,964

Shares Outstanding: 19,629,906

2025-12-31

51.78%

Inst. Shares: 19,272,007

Shares Outstanding: 37,221,211

2025-09-30

86.37%

Inst. Shares: 35,086,131

Shares Outstanding: 40,623,364

2025-06-30

87.40%

Inst. Shares: 35,494,820

Shares Outstanding: 40,612,907

2025-03-31

79.78%

Inst. Shares: 32,357,061

Shares Outstanding: 40,559,355

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	18,167,964	19,629,906	92.55%
2025-12-31	19,272,007	37,221,211	51.78%
2025-09-30	35,086,131	40,623,364	86.37%
2025-06-30	35,494,820	40,612,907	87.40%
2025-03-31	32,357,061	40,559,355	79.78%
2024-12-31	35,622,479	37,437,652	95.15%
2024-09-30	33,260,580	37,590,727	88.48%
2024-06-30	30,126,375	36,103,187	83.45%
2024-03-31	29,972,490	35,685,422	83.99%
2023-12-31	24,335,553	29,447,119	82.64%
2023-09-30	21,330,242	29,668,247	71.90%
2023-06-30	20,648,316	29,602,458	69.75%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Keros Therapeutics, Inc. (KROS) — SEC Financial Statements & Analysis

Keros Therapeutics, Inc. (KROS) is a pharmaceutical preparations company. Keros Therapeutics, Inc. trades on Nasdaq as: KROS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Keros Therapeutics, Inc. reported a -93.55% year-over-year revenue growth, a Debt-to-Equity ratio of 0.10x, a Price-to-Sales (P/S) ratio of 14.11x (TTM), a Price-to-Book (P/B) ratio of 0.81x (TTM), at a market cap of $211.86M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -93.55%
Debt To Equity: 0.10x
P/S TTM: 14.11x
P/B TTM: 0.81x
Market Cap: $211.86M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Keros Therapeutics, Inc. in?

Keros Therapeutics, Inc. (KROS) operates in the Pharmaceutical Preparations industry.

What is KROS's market cap?

Keros Therapeutics, Inc. (KROS) has a market capitalization of $211.86M as of 2026-06-30.

What exchange does KROS trade on?

Keros Therapeutics, Inc. (KROS) trades on the Nasdaq.